Ensysce Biosciences, Inc. (ENSC) Company Sales Volume

Ensysce Biosciences (ENSC) develops abuse-resistant opioid medications, relying on royalties from the licensing of its patents. The business's success depends on FDA approval and the effectiveness of its platform in preventing overdoses. Demand for safe pain management is driving the search for B2B partners. The company's sales performance dynamics demonstrate current operational liquidity, with the metric reaching 0.00, which is critical for accurate portfolio rebalancing.

Ensysce Biosciences Inc. (ENSC) Company Sales: for the period 07/04/2022 - 11/13/2026

Comprehensive metric breakdowns and analytics for Ensysce Biosciences Inc. (ENSC)

- market price and analyst price targets:

Market Price Ensysce|ENSC - Price Target Chart

- market capitalization details:

Market Capitalization Ensysce Biosciences, Inc.|ENSC - Total Company Value

- issuer book value statistics:

Net Assets per Share Ensysce Biosciences|ENSC - Company Net Assets|Market-to-Book Ratio ensysce.com|ENSC - Aggregate Company Assets

- company liabilities and liquidity data:

- earnings and market multiples details:

ENSC - Net Profit|Company Profit Forecast Ensysce Biosciences|ENSC - Price to Earnings Ratio|Projected Price to Earnings Ratio Ensysce|ENSC - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Ensysce Biosciences, Inc.|ENSC - Operating profit EBITDA|Net earnings per share for the last 12 months Ensysce Biosciences|ENSC - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months ensysce.com|ENSC - Earnings growth in current year|Expected net earnings per share growth next year Ensysce Biosciences

- issuer revenue and sales details:

ENSC - Company Revenue|Company Revenue Forecast Ensysce|ENSC - P/S Multiple|Forward Price-to-Revenue Multiple Ensysce Biosciences, Inc.

Summary company analysis:ENSC (ensysce.com)

Manufactured product of Ensysce Biosciences

This indicator measures the aggregate daily cash flow from product sales, allowing for an assessment of operational efficiency and market demand through the aggregation of daily receipts. By analyzing the sales volume dynamics of Ensysce Biosciences (ENSC), an investor can track the commercialization rates of the proprietary TAAP and MPAR platforms, where an upward trend confirms the successful implementation of opioid overdose prevention technologies into clinical practice.

Competing companies